Formulation and characterization of folate receptor-targeted PEGylated liposome encapsulating bioactive compounds from
Apoptosis
Breast cancer
Folate receptor
Kappaphycus alvarezii
Liposome
Journal
3 Biotech
ISSN: 2190-572X
Titre abrégé: 3 Biotech
Pays: Germany
ID NLM: 101565857
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
19
10
2019
accepted:
11
02
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
ppublish
Résumé
This study aimed to formulate and characterize the folate receptor-targeted PEGylated liposome encapsulating bioactive compounds from
Identifiants
pubmed: 32158632
doi: 10.1007/s13205-020-2132-7
pii: 2132
pmc: PMC7040115
doi:
Types de publication
Journal Article
Langues
eng
Pagination
136Informations de copyright
© King Abdulaziz City for Science and Technology 2020.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare no competing financial interest.
Références
Int J Nanomedicine. 2018 Jul 30;13:4417-4431
pubmed: 30104875
Apoptosis. 2011 Oct;16(10):1042-53
pubmed: 21779837
Pharm Res. 2007 Mar;24(3):438-49
pubmed: 17252188
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1055-8
pubmed: 15094205
Trends Pharmacol Sci. 2009 Nov;30(11):592-9
pubmed: 19837467
Biomed Pharmacother. 2016 Dec;84:1300-1312
pubmed: 27810787
J Control Release. 2012 May 10;159(3):393-402
pubmed: 22286008
3 Biotech. 2019 May;9(5):185
pubmed: 31065485
Biomed Pharmacother. 2017 Mar;87:296-301
pubmed: 28063411
Crit Rev Food Sci Nutr. 2009 Jun;49(6):577-606
pubmed: 19484636
Nat Rev Drug Discov. 2005 Feb;4(2):145-60
pubmed: 15688077
Cells. 2018 Jul 21;7(7):
pubmed: 30037060
Biochim Biophys Acta. 1990 Nov 2;1029(1):91-7
pubmed: 2223816
FEBS Lett. 1990 Jul 30;268(1):235-7
pubmed: 2384160
Food Chem. 2018 Feb 1;240:799-807
pubmed: 28946344
Cancer Cell Int. 2013 Jun 27;13(1):65
pubmed: 23806172
Int J Pharm. 2008 Sep 1;361(1-2):56-63
pubmed: 18573626
Drug Dev Ind Pharm. 2005 Mar;31(3):281-91
pubmed: 15830724
Anticancer Agents Med Chem. 2018;18(13):1900-1918
pubmed: 29956638
Drug Discov Today. 2018 Feb;23(2):434-447
pubmed: 29107095
Cancer Invest. 2001;19(4):424-36
pubmed: 11405181
J Pharm Sci. 2008 Sep;97(9):3518-90
pubmed: 18200527
Drug Dev Ind Pharm. 2003 Apr;29(4):451-67
pubmed: 12737538
J Control Release. 2004 Nov 24;100(2):247-56
pubmed: 15544872
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
Expert Opin Drug Deliv. 2008 Mar;5(3):309-19
pubmed: 18318652
J Control Release. 2003 Feb 21;87(1-3):167-76
pubmed: 12618033
In Vitro Cell Dev Biol Anim. 2015 Jun;51(6):630-43
pubmed: 25862331
Pharm Res. 1994 Aug;11(8):1127-31
pubmed: 7971713
J Biol Res (Thessalon). 2014 May 19;21(1):6
pubmed: 25984489
Mol Pharm. 2011 Jun 6;8(3):683-700
pubmed: 21491921
Bioconjug Chem. 1999 Mar-Apr;10(2):289-98
pubmed: 10077479
Biotechnol Adv. 2016 Jul-Aug;34(4):343-353
pubmed: 27071534
Colloids Surf B Biointerfaces. 2017 Aug 1;156:203-212
pubmed: 28531877
Nat Biotechnol. 1999 Jan;17(1):94-5
pubmed: 9920278
Biochem Biophys Res Commun. 2011 Feb 11;405(2):291-6
pubmed: 21219864
Pharmaceutics. 2019 Apr 15;11(4):
pubmed: 30991703
J Nat Prod. 1985 Mar-Apr;48(2):223-35
pubmed: 3839259
Theranostics. 2018 Jun 24;8(14):3949-3963
pubmed: 30083272
Pharmacogn Mag. 2015 Apr-Jun;11(42):345-55
pubmed: 25829774
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
pubmed: 12612647
Sci Rep. 2018 Aug 15;8(1):12199
pubmed: 30111833
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Sci Pharm. 2010;78(1):93-101
pubmed: 21179372
J Oncol. 2010;2010:214186
pubmed: 21461373
Anticancer Agents Med Chem. 2019;19(16):1966-1982
pubmed: 31267878
J Biomed Mater Res A. 2006 Sep 1;78(3):550-7
pubmed: 16736484
Cancer Biol Ther. 2004 Jul;3(7):641-50
pubmed: 15136766
Int J Cancer. 2002 Sep 1;101(1):78-85
pubmed: 12209592